FDA Alert
FDA Alert
09/30/2024
Miranda Manier, BA
Two randomized, double-blind studies demonstrated that a new antipsychotic treatment for adult patients with schizophrenia may lead to a meaningful reduction in symptoms.
09/30/2024
FDA Alert
FDA Alert
09/27/2024
Anthony Calabro, MA
The nasal spray is the first vaccine for the prevention of influenza that does not need to be administered by a health care provider.
09/27/2024
FDA Alert
FDA Alert
08/23/2024
Anthony Calabro, MA
The first nalmefene hydrochloride auto-injector is another emergency treatment tool to reverse known or suspected opioid overdose.
08/23/2024
FDA Alert
FDA Alert
08/19/2024
Anthony Calabro, MA
The nasal spray is the first FDA-approved epinephrine product for the treatment of anaphylaxis not to be administered by injection.
08/19/2024
FDA Alert
FDA Alert
08/19/2024
Anthony Calabro, MA
The nasal spray is the first FDA-approved epinephrine product for the treatment of anaphylaxis not to be administered by injection.
08/19/2024
FDA Alert
FDA Alert
07/31/2024
Anthony Calabro, MA
The first orally disintegrating birth control tablet was designed for individuals who have trouble swallowing their medication.
07/31/2024
FDA Alert
FDA Alert
04/18/2024

Anthony Calabro, MA

Anthony Calabro, MA
The FDA approved givinostat, a nonsteroidal oral medication, for treating patients 6 years of age or older with Duchenne muscular dystrophy.
04/18/2024
FDA Alert
FDA Alert
03/21/2024

Anthony Calabro, MA

Anthony Calabro, MA
The FDA approved resmetirom for the treatment of adults with metabolic dysfunction-associated steatohepatitis with moderate-to-advanced liver fibrosis.
03/21/2024
FDA Alert
FDA Alert
03/21/2024

Anthony Calabro, MA

Anthony Calabro, MA
On March 8, the FDA approved the injectable weight loss medication, semaglutide, for reducing the risk of cardiovascular events such as heart attack, stroke, and cardiovascular death in adults with heart...
03/21/2024
FDA Alert
FDA Alert
03/04/2024
Anthony Calabro, MA
The FDA approved irinotecan liposome with oxaliplatin, fluorouracil, and leucovorin as a first-line regimen for the management of patients with metastatic pancreatic adenocarcinoma.
03/04/2024